An interventional study of Camino Intervention in HIV Infections, sponsored by American University. Recruiting at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by American University · Not applicable, Interventional, and Prevention
Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.
Among the 2,802 studies in HIV Infections with a site in United States, this one is the 1,223rd largest by planned enrollment of the 2,150 interventional ones that give a count, is one of 26 that started in 2026, is one of 718 with no phase, reaches primary completion later than 123 of the 137 other live ones, and was the 2,799th registered.
4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.
This study's planned enrollment of 50 is below the median of 80 across 3,489 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →83 of the 2,802 studies in HIV Infections with a site in United States are open now.
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 158 HIV Infections studies recruiting now, 104 (66%) set no upper age limit and 41 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →2,802 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 749 · Phase 2 588 · Phase 3 337 · Phase 4 157
First in 1984; this study’s year is marked. 26 started in 2026.
Median enrollment 60 across the 2,150 interventional studies, 135 across the 350 observational. Of the 2,530 that completed or were terminated, 558 (22%) have results posted.
857 of 2,802 have an industry lead sponsor. The 10 most frequent:
American University is the lead sponsor of 20 studies on the registry; 4 are open to participants now.
American University has 1 study filed under HIV Infections — fewer than ten, so there is no comparison to draw.
51 of the studies in HIV Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT04577313University of ConnecticutHIV Treatment Adherence Dose Determination Trial | 2026-11-30 |
| NCT06679751Boston Medical CenterInfectious Disease (ID) Testing OUtreach in Carceral Hubs | 2026-12 |
| NCT06868641Columbia UniversityThe TAIL-PrEP Study | 2026-12 |
Among the 2,802 studies in HIV Infections with a site in United States, from their registry updates:
The Camino Study evaluates a status-neutral, multi-level pilot intervention designed to improve HIV prevention and care engagement among Latin Americans with unmet HIV prevention and care needs. The intervention combines legal services with peer navigation to reduce fear of healthcare engagement, reduce stress, and improve access to HIV prevention and care services.
The study will enroll 50 Latin American participants in the Washington, DC, and Oakland, California areas. Using a quasi-experimental wait-list control design, the study will compare HIV outcomes among participants who receive the Camino intervention with those on a rolling waitlist over 18 months. Primary outcomes include HIV testing within the past six months and uptake of pre-exposure prophylaxis (PrEP), as well as HIV care visit attendance, antiretroviral therapy (ART) adherence, and viral load among people living with HIV. The study will also examine legal, social, and mental health factors associated with HIV prevention and care engagement and assess the feasibility of testing the intervention at a larger scale.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the Camino intervention, which includes peer navigation to support engagement in HIV prevention and care and legal services. Peer navigation begins immediately after enrollment. Participants receive the individual legal consultation when an attorney becomes available; therefore, the timing of receipt of the legal consultation varies across participants. Participants are followed for 18 months.
Behavioral: Camino Intervention
Camino is a multicomponent intervention designed to improve engagement in HIV prevention and care. Participants receive culturally and linguistically appropriate peer navigation beginning after enrollment to help identify and address barriers to HIV prevention and care and connect participants with relevant health and social services. The intervention also includes individualized consultation with an attorney and legal services and navigation. Because attorney availability varies, participants receive the individual legal consultation at different times during follow-up.
HIV testing within the past 6 months
Survey data and medical records will be used to assess HIV testing within the past 6 months among participants not living with HIV.
Time frame: 18 months
PrEP Uptake
Survey data and medical records will be used to assess initiation of pre-exposure prophylaxis (PrEP) among participants who are HIV-negative and eligible for PrEP.
Time frame: 18 months
HIV Care Visit Attendance
Medical records will be used to assess HIV care visit attendance among participants living with HIV.
Time frame: 18 months
Antiretroviral Therapy Adherence
Medical records and survey data will be used to assess adherence to antiretroviral therapy (ART) among participants living with HIV who are prescribed ART.
Time frame: 18 months
HIV Viral Load
Medical records will be used to assess HIV viral load among participants living with HIV.
Time frame: 18 months
Plan to share: Yes — De-identified individual participant data collected during the study will be shared through the NIMH Data Archive (NDA) for secondary research use in accordance with NIH and NIMH data-sharing requirements.
Supporting information: Study protocol
Time frame: Data and supporting documentation will be submitted and made available in accordance with NIMH Data Archive submission and sharing timelines and will remain available according to NDA policies.
Access criteria: Data will be available through the NIMH Data Archive to authorized researchers who meet NDA access requirements. Researchers must submit a formal data access request and agree to NDA data use and confidentiality requirements.
Data sharing details ↗ · nda.nih.gov
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Feb 2029, 31 months after the start.
Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 31 months is above that.
Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
American University